Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 4,720 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Signs and Symptoms, Respiratory Clear all

Conditions: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Alemtuzumab; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: La Jolla, California • La Verne, California • Aurora, Colorado + 4 more

Conditions: Neoplasm Metastasis, Non-Small Cell Lung Cancer
Interventions: zongertinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more

Conditions: Opioid Toxicity, Pupillary Miosis, Respiratory Depression
Interventions: Remifentanil Hydrochloride, Pupillometry measurement; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Long COVID, Long COVID Syndrome, Long COVID-19 Syndrome, PASC, PASC Post Acute Sequelae of COVID 19
Interventions: accelerated intermittent theta burst stimulation; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Asthma
Interventions: Semaglutide Pen Injector 2.4mg weekly, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Respiratory Distress Syndrome, Cardiac Failure, Extracorporeal Membrane Oxygenation Complication, Respiratory Failure, Renal Failure, Critical Illness, Pulmonary Disease
Interventions: Ventilator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Long Haul COVID-19, Post-Acute COVID-19 Syndrome, Anosmia, Olfaction Disorders
Interventions: Sodium Citrate, Normal Saline, Olfactory Training Kit - "The Olfactory Kit, by AdvancedRx"; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Post-Acute COVID-19 Syndrome
Interventions: NeuroFlex (computerized gamified tasks); Other
Lead sponsor: UConn Health; Other
Eligibility: 60 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Obstructive Sleep Apnea, Metabolic Syndrome X
Interventions: sleep disruption, sleep with and without positive pressure; Procedure
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sleep Apnea, Obstructive, Pregnancy, Obesity, Morbid
Interventions: ApneaLink Air, Berlin Quesionnaire, Epworth Sleepiness Scale, STOP-BANG questionnaire, Physical exam; Device · Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Avelumab, PF-06463922, Crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Dayton Children's Hospital; Other
Eligibility: 7 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Group 1, Group 2; Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
Interventions: Quercetin 1000 mg, Quercetin 500 MG, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Overweight, Obstructive Sleep Apnoea
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: San Diego, California • Miami, Florida • Naples, Florida + 13 more

Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions: A2B530, xT-Onco with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more

Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions: SNS-101 (anti-VISTA), Cemiplimab; Drug
Lead sponsor: Sensei Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more

Conditions: Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions: Enbrel; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Cardiovascular Abnormalities
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Anosmia, Hyposmia, Parosmia, Olfactory Disorder
Interventions: Stellate Ganglion Block; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Educational brochures; Behavioral
Lead sponsor: VA Midwest Health Care Network; Federal
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib + Savolitinib, Savolitinib + Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Duarte, California • Sacramento, California

Conditions: Colonoscopy, Oxygenation, Ventilation
Interventions: Oxygen via nasal cannula, Oxygen via SuperNO2VA nasal mask; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients

Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction

Brain-Training Treatment for Long COVID in Older Adults

Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress

Obstructive Sleep Apnea in Pregnancy

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers

Biological Effects of Quercetin in COPD Phase II

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

Effects of Weight Loss on Cardio-respiratory Function

Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

Effect of Educational Intervention in Patients With Low-Risk Chronic Obstructive Pulmonary Disease

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Comparison of Oxygenation and Ventilation With a Novel Nasal Mask Versus Standard of Care During Colonoscopy